MedTrace Logo

Sertraline in Generalized Social Phobia With Co-Occurring Anxiety and Mood Disorders

NCT00182533 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 170

Last updated 2018-03-22

No results posted yet for this study

Summary

Selective serotonin reuptake inhibitors (SSRIs) including sertraline have been found to be effective in the treatment of generalized social phobia (GSP). However, virtually all of the current treatment studies with medicines, including the SSRIs, have excluded patients with social phobia who have other co-occurring conditions. In fact, 80% of individuals suffering with primary social phobia have at least one other anxiety. This study will evaluate the safety and efficacy of sertraline in the treatment of generalized social phobia with co-occurring anxiety and mood disorders.

Conditions

Interventions

DRUG

Sertraline

25 - 200 mg/day x 16 weeks

DRUG

Placebo

25 - 200 mg/day x 16 weeks

Sponsors & Collaborators

  • Pfizer

    collaborator INDUSTRY

  • Hamilton Health Sciences Corporation

    lead OTHER

Principal Investigators

  • Michael Van Ameringen, MD, FRCPC · Hamilton Health Sciences Corporation

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-07-31
Primary Completion
2018-01-31
Completion
2018-01-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00182533 on ClinicalTrials.gov